Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 2.02, 9.01 · 8-K

Twist Bioscience Corporation

TWSTNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On May 4, 2026, Twist Bioscience Corporation (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.…

Filed May 4, 2026Accepted May 4, 2026, 7:21 AM EDTCIK 1581280Accession 0001581280-26-000037
Share

Company context

At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets. We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal - more experiments, more iterations, more chances for remarkable discoveries.

Current securities

Recent company filings

  1. Results of Operations and Financial ConditionNov 12, 2026
  2. SCHEDULE 13G/A - filed by Artisan Partners Limited Partnership regarding Twist Bioscience CorpNov 12, 2026
  3. SCHEDULE 13G - filed by STATE STREET CORP regarding Twist Bioscience CorpNov 10, 2026
  4. SCHEDULE 13G/A - filed by FMR LLC regarding Twist Bioscience CorpNov 5, 2026
  5. 144 filingSep 21, 2026

Registered securities in this filing

Twist Bioscience Corporation · 8-K · Filed 2026-05-04

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock

Symbol
TWST
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: c-1

Dimensions: Not supplied

Accession 000158128026000037 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition. On May 4, 2026, Twist Bioscience Corporation (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 (by filename) twst-2026331xex991.htm

EX-99.1 2 twst-2026331xex991.htm EX-99.1 Document Exhibit 99.1 Twist Bioscience Reports Fiscal Second Quarter 2026 Financial Results - Record revenue of $110.7 million in 2QFY26; Increase of more than 19% over $92.8 million in 2QFY25; 13th consecutive quarter of sequential growth - - Gross margin of 51.6% in 2QFY26; Improvement of approximately 2 margin points versus 2QFY25 - - Revenue guidance raised to $442-$447M; Reiterating Q4 FY26 Adj EBITDA breakeven - SOUTH SAN FRANCISCO, Calif. -- (May 4, 2026) - Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today reported financial results and business highlights for the second quarter ended March 31, 2026. "We had a strong performance in the first half of fiscal 2026, ending the second quarter with our thirteenth consecutive quarter of growth. Revenue exceeded guidance, coming in at $110.7 million, growth of over 19% compared to the second quarter of 2025," said Emily M. Leproust, Ph. D., CEO and co-founder of Twist Bioscience. "As we look ahead, we remain focused on delivering consistent, measurable growth designed to scale over time. We expect to chart toward profitability while simu…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.